Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $6.6 million.

  • Revolution Medicines' Depreciation & Amortization (CF) rose 25.64% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 18.35%. This contributed to the annual value of $6.6 million for FY2024, which is 30.09% up from last year.
  • As of FY2024, Revolution Medicines' Depreciation & Amortization (CF) stood at $6.6 million, which was up 30.09% from $5.0 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Depreciation & Amortization (CF) ranged from a high of $6.6 million in FY2024 and a low of $2.6 million during FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $5.0 million (2023), whereas its average is $5.2 million.
  • Data for Revolution Medicines' Depreciation & Amortization (CF) shows a peak YoY soared of 30.09% (in 2024) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Depreciation & Amortization (CF) (Yearly) stood at $2.6 million in 2020, then increased by 18.73% to $3.1 million in 2021, then climbed by 28.13% to $4.0 million in 2022, then rose by 26.94% to $5.0 million in 2023, then soared by 30.09% to $6.6 million in 2024.